Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Conditions
Interventions
Valbenazine
Placebo oral capsule
Locations
49
United States
Neuricrine Clinical Site
Sun City, Arizona, United States
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Rogers, Arkansas, United States
Neurocrine Clinical Site
Anaheim, California, United States
Neurocrine Clinical Site
Fullerton, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Start Date
April 17, 2018
Primary Completion Date
July 16, 2019
Completion Date
July 16, 2019
Last Updated
May 17, 2022
NCT06678737
NCT03851484
NCT04449068
NCT05558566
NCT06194305
NCT06873841
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions